Tuesday, November 22, 2011

Enbrel® (etanercept) Patent Issued

THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ:AMGN) today issued the following statement:

Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel® (etanercept). This patent is owned by Hoffman-La Roche Inc.  ("Roche") and exclusively licensed to Amgen. Immunex Corporation (acquired by Amgen in 2002) originally licensed this patent application from Roche in 1999, and in 2004, Amgen paid Roche a one-time payment and obtained an exclusive, fully paid-up license to the application which issued today as the ‘182 patent. The patent describes and claims the fusion protein that is etanercept, and by statute, the ‘182 patent has a term of 17 years from today.

Read the rest of this entry

Posted in Press Releases

Tuesday, November 15, 2011

The Lancet Publishes Results Demonstrating XGEVA® Significantly Prolonged Bone Metastasis-free Survival in Men With Prostate Cancer

XGEVA Prevented or Delayed the Onset of Bone Metastases in Patients With Prostate Cancer

THOUSAND OAKS, Calif., Nov. 15, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) announced today the publication of results from a Phase 3 trial (the ‘147 study) that evaluated XGEVA® (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic castration-resistant prostate cancer (CRPC). Published in The Lancet, the study found XGEVA significantly prolonged bone metastasis-free survival, delayed time to bone metastasis and reduced the risk of symptomatic bone metastases. This study is the first to demonstrate that targeting the bone microenvironment prevents bone metastasis in men with prostate cancer.

Read the rest of this entry

Posted in Press Releases

Tuesday, November 15, 2011

Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union

THOUSAND OAKS, Calif., Nov. 15, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix® (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). This approval of Vectibix applies to all 27 European Union (EU) member states. Prior to this approval, Vectibix had received conditional approval in the EU as monotherapy. The monotherapy indication was also further revised to state that Vectibix is indicated for the treatment of patients with wild-type KRAS mCRC as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Read the rest of this entry

Posted in Press Releases

Monday, November 14, 2011

Amgen Statement on European Investor Visit

THOUSAND OAKS, Calif., Nov. 14, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ:AMGN) today issued the following statement:

Amgen will be meeting with investors in Europe this week with a view to raise $1-1.5 billion in Euro and Sterling denominated debt to support its share repurchase program, as well as for general corporate purposes. The timing of this potential offering will be subject to market conditions.

Read the rest of this entry

Posted in Press Releases

Monday, November 07, 2011

Amgen Announces Plan to Launch Tender Offer and Launch of Senior Notes Offering

THOUSAND OAKS, Calif., Nov. 7, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced its plan to launch a modified Dutch auction tender offer to purchase up to $5 billion of its common stock, par value $0.0001 per share ("Common Stock"). Amgen also announced a public offering of its senior notes, the proceeds of which will be used to fund the tender offer and for general corporate purposes.

Read the rest of this entry

Posted in Press Releases